Advances in the pathophysiology of constitutive and inducible cyclooxygenases: Two enzymes in the spotlight

Biochemical Pharmacology

Volumn 65, Issue 2, 2003, Pages 153-159

  Parente, Luca ^a   Perretti, Mauro ^b  

^a UNIVERSITY OF SALERNO   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cyclooxygenase; Inflammation; NSAIDs; Prostaglandins

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLUTATHIONE; GLUTATHIONE TRANSFERASE; INDOMETACIN; LEUKOTRIENE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDOLEUKOTRIENE; PEROXIDASE; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROTEIN SUBUNIT; ROFECOXIB; THROMBOXANE A2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; BLOOD VESSEL TONE; CONTROLLED STUDY; DATA ANALYSIS; DIGESTIVE SYSTEM INJURY; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; GASTROINTESTINAL MUCOSA; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; HYPERALGESIA; HYPOTHESIS; INFLAMMATION; INFLAMMATORY DISEASE; KIDNEY BLOOD FLOW; KIDNEY DEVELOPMENT; KIDNEY FUNCTION; LIPID METABOLISM; MOUSE; NOCICEPTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; RAT; REVIEW; THROMBOCYTE; THROMBOSIS;

EID: 0037437765     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01422-3     Document Type: Note

References (55)

1. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271:1996;33157-33160.
2. Marnett L.J., Rowlinson S.W., Goodwin D.C., Kalgutkar A.S., Lanzo C.A. Arachidonate acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem. 274:1999;22903-22906.
3. Katori M., Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm. Res. 49:2000;367-392.
4. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345:2001;433-442.
5. Hawkey C.J. COX-2 inhibitors. Lancet. 353:1999;307-314.
6. Talley J.J., Brown D.L., Carter J.S., Graneto M.J., Koboldt C.M., Masferrer J.L., Perkins W.E., Rogers R.S., Shaffer A.F., Zhang Y.Y., Zweifel B.S., Seibert K. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J. Med. Chem. 43:2000;775-777.
7. Riendeau D., Percival M.D., Brideau C., Charleson S., Dube D., Ethier D., Falgueyret J.-P., Friesen R.W., Gordon R., Greig G., Guay J., Mancini J., Ouellet M., Wong E., Xu L., Boyce S., Visco D., Girard Y., Prasit P., Zamboni R., Rodger I.W., Gresser M., Ford-Hutchinson A.W., Young R.N., Chan C.-C. Eterocoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296:2001;558-566.
8. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:1998;97-120.
9. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 294:2001;1871-1875.
10. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. U.S.A. 91:1994;12013-12017.
11. Crofford L.J., Wilder R.L., Ristimaki A.P., Sano H., Remmers E.F., Epps H.R., Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids. J. Clin. Invest. 93:1994;1095-1101.
12. Nantel F., Denis D., Gordon R., Northey A., Cirino M., Metters K.M., Chan C.C. Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation. Br. J. Pharmacol. 128:1999;853-859.
13. Anderson G.D., Hauser S.D., McGarity K.L., Bremer M.E., Isakson P.C., Gregory S.A. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J. Clin. Invest. 97:1996;2672-2679.
14. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G., Isakson P.C., Seibert K. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 91:1994;3228-3232.
15. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., Isakson P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13313-13318.
16. Wallace J.L., Chapman K., McKnight W. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br. J. Pharmacol. 126:1999;1200-1204.
17. Wallace J.L., Bak A., McNight W., Asfaha S., Sharkey K.A., MacNaughton W.K. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology. 115:1998;101-109.
18. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C., Mahler J.F., Lee C.A., Goulding E.H., Kluckman K.D., Kim H.S., Smithies O. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 83:1995;483-492.
19. Morham S.G., Langenbach R., Loftin C.D., Tiano H.F., Vouloumanos N., Jennette J.C., Mahler J.F., Kluckman K.D., Ledford A., Lee C.A., Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 83:1995;473-482.
20. Ochi T., Goto T. Differential effect of FR122047, a selective cyclooxygenase-1 inhibitor, in rat chronic models of arthritis. Br. J. Pharmacol. 135:2002;782-788.
21. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., Willoughby D.A. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5:1999;698-701.
22. Ferreira S.H. Prostaglandins, aspirin-like drugs and analgesia. Nature. 240:1972;200-203.
23. 2 . Prostaglandins. 16:1978;31-37.
24. Ballou L.R., Botting R.M., Goorha S., Zhang J., Vane J.R. Nociception in cyclooxygenase isozyme-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10272-10276.
25. Ochi T., Motoyama Y., Goto T. The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. Eur. J. Pharmacol. 391:2000;49-54.
26. Kargman S., Charleson S., Cartwright M., Frank J., Riendeau D., Mancini J., Evans J., O'Neill G. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology. 111:1996;445-454.
27. Vane JR, Botting RM. Formation and actions of prostaglandins and inhibition of their synthesis. In: Vane JR, Botting RM, editors. Therapeutic Roles of Selective COX-2 Inhibitors. London: William Harvey Press; 2001, p. 1-47.
28. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Bosi Ferraz M., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J. For the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343:2000;1520-1528.
29. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Verburg K.M., Geis G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA. 284:2000;1247-1255.
30. Zimmermann K.C., Sarbia M., Schrör K., Weber A.-A. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol. Pharmacol. 54:1998;536-540.
31. Wallace J.L., McNight W., Reuter B.K., Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 119:2000;706-714.
32. Tanaka A., Hase S., Miyazawa T., Takeuchi K. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J. Pharmacol. Exp. Ther. 300:2002;754-761.
33. Wallace J.L. Selective COX-2 inhibitors: is the water becoming muddy? Trends Pharmacol. Sci. 20:1999;4-6.
34. Mizuno H., Sakamoto C., Matsuda K., Wada K., Uchida T., Noguchi H., Akamatsu T., Kasuga M. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 112:1997;387-397.
35. Schmassmann A., Peskar B.M., Stettler C., Netzer P., Stroff T., Flogerzi B., Halter F. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br. J. Pharmacol. 123:1998;795-804.
36. Maricic N., Ehrlich K., Gretzer B., Schuligoi R., Respondek M., Peskar B.M. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br. J. Pharmacol. 128:1999;1659-1666.
37. Reuter B.K., Ashafa S., Buret A., Sharkey K.A., Wallace J.L. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J. Clin. Invest. 98:1996;2076-2086.
38. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5:1999;1418-1423.
39. Paleolog E.M., Fava R.A. Angiogenesis in rheumatoid arthritis: implications for future therapeutics. Springer Semin. Immunopathol. 20:1998;73-94.
40. Harris R.C., McKanna J.A., Akai Y., Jacobson H.R., Dubois R.N., Breyer M.D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. 94:1994;2504-2510.
41. Nantel F., Meadows E., Denis D., Connolly B., Metters K.M., Giaid A. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett. 457:1999;475-477.
42. Zhang M.-Z., Wang J.-L., Cheng H.-F., Harris R.C., McKanna J.A. Cyclooxygenase-2 in rat nephron development. Am. J. Physiol. 273:1997;F994-F1002.
43. Dinchuk J.E., Car B.D., Focht R.J., Johnston J.J., Jaffee B.D., Covington M.B., Contel N.R., Eng V.M., Collins R.J., Czerniak P.M., Gorry S.A., Trzaskos J.M. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 378:1995;406-409.
44. Catella-Lawson F., McAdam B., Morrison B.W., Kapoor S., Kujubu D., Antes L., Lasseter K.C., Quan H., Gertz B.J., FitzGerald G.A. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289:1999;735-741.
45. Rocha J.L., Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet. 357:2001;1946-1947.
46. Patrono C. Aspirin as an anti-platelet drug. N. Engl. J. Med. 330:1994;1287-1294.
47. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U.S.A. 96:1999;272-277.
48. Praticò D., Tillmann C., Zhang Z.-B., Li H., FitzGerald G.A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 98:2001;3358-3363.
49. Crofford L.J., Oates J.C., McCune W.J., Gupta S., Kaplan M.J., Catella-Lawson F., Morrow J.D., McDonagh K.T., Schmaier A.H. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum. 43:2000;1891-1896.
50. Adderley S.R., Fitzgerald D.J. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J. Biol. Chem. 274:1999;5038-5046.
51. Shinmura K., Tang X.-L., Wang Y., Xuan Y.-T., Liu S.-Q., Takano H., Bhatnagar A., Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10197-10202.
52. Boers M. NSAIDs and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet. 357:2001;1222-1223.
53. Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J. Rheumatol. 28:2001;2375-2382.
54. Fiorucci S., Meli R., Bucci M., Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol. 62:2001;1433-1438.
55. Wallace J.L., Carter L., McNight W., Tries S., Laufer S. ML3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur. J. Pharmacol. 271:1994;525-531.